Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05600088
Other study ID # CT-CD-P03-1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 18, 2022
Est. completion date July 31, 2025

Study information

Verified date March 2024
Source Cryotherapeutics SA
Contact Danny Detiege, RN
Phone +32467024773
Email dde@cryotherapeutics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at high-risk of rupture which would cause a major heart attack. The CTS is used to apply local freezing of the lesion using a balloon catheter, controlled by a console that regulates in- and outflow of a cooling agent into the catheter. The treatment is expected to stabilize the lesion, diminishing the risk of rupture. The study will enrol subjects with acute coronary disease who have suitable coronary lesions. Subjects will be followed for 1 year after the CTS treatment. Baseline identification of lesions will be done using Coronary CT-angiography (CCTA), which will be repeated at 3 and 9 months after procedure.


Description:

The POLARSTAR study is an early feasibility study to evaluate the safety and performance of the CryoTherapy System (CTS) medical device, consisting of a console and a balloon catheter. The CTS is designed to deliver local cryo-energy to vulnerable plaque lesions in the coronary arteries, aiming to stabilize the plaque to reduce the risk of rupture and subsequent cardiac events. The study will enrol up to 10 subjects with NSTEMI or unstable angina, who underwent successful Percutaneous Coronary Intervention (PCI) of their culprit coronary lesion, and who were identified to have presence of at least 1 non-culprit suitable plaque lesion at high-risk of rupture. After providing informed consent the subjects will undergo a Coronary CT-angiography (CCTA) to confirm suitability of the coronary plaque lesion. A single high-risk plaque lesion will be treated by the investigators, with Intra-vascular Ultrasound (IVUS) imaging prior to and after CTS treatment. Subjects will be followed clinically for up to one year after the CTS treatment, and will have follow-up CCTA assessments at 3 and 9 months post-procedure. Primary endpoint will be Major cardiac events rate at 3 months post procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 31, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is at least 18 years old. 2. Subject has acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria: 1. Non-ST-segment elevation myocardial infarction (NSTEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis 2. Unstable angina 3. Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion. 4. Subject has at least one high-risk plaque meeting the criteria below: 1. Located in a non-culprit vessel, 2. High-risk plaque lesion on CCTA and at least one of the following features: 1. Presence of low-attenuation plaque (HU<50) and/or 2. Positive remodelling (remodelling index >1.1) and/or 3. Napkin ring sign and/or 4. Plaque burden =70% 3. Lesion length = 20 mm. 4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR>0.80 or non-hyperemic pressure ratios (NHPR) >0.89). 5. Reference vessel diameter (RVD) < 3.75 mm and > 2.00 mm in diameter 6. Investigator considers that lesions are accessible. 7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment. 5. Subject is able to provide consent and has signed and dated the informed consent form. Exclusion Criteria: 1. Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP). 2. Subject has ongoing ST-segment elevation myocardial infarction. 3. Subject had a procedural complication during the Acute coronary syndrome (ACS) PCI procedure. 4. Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure. 5. Subject has known reduced Left Ventricular Ejection Fraction < 30%. 6. Subject has known severe valvular heart disease. 7. Subject has known severe renal insufficiency (eGFR <30 ml/min/1.72 m2). 8. Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy < 12 months. 9. Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint. 10. Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device). Angiographic exclusion criteria: 1. Visible distal embolization/no-reflow following culprit lesions PCI. 2. Left main coronary artery disease (visual diameter stenosis > 50%). 3. Stent thrombosis/restenosis as a culprit lesion. 4. CTS lesion involving a bifurcation (defined as lesions involving side branches >2.0 mm). 5. Angiographic or CCTA evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion. 6. Thrombotic lesions 7. Ostial lesions

Study Design


Intervention

Device:
CryoTherapy System (CTS)
local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy

Locations

Country Name City State
Georgia Israeli-Georgian Research Clinic Helsicore Tbilisi
Georgia Tbilisi Heart Center Tbilisi
Lithuania Hospital of Lithuanian University of health sciences Kauno Klinikos Kaunas
Lithuania Vilnius University Hospital Santaros Klinikos Vilnius

Sponsors (2)

Lead Sponsor Collaborator
Cryotherapeutics SA CoreAalst BV

Countries where clinical trial is conducted

Georgia,  Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Rate of Cryotherapy related adverse events Any cryotherapy procedure related complication defined as coronary artery dissection (angiographic dissection = NHLBI type B), acute vessel closure, life threatening arrythmia, need for bailout stenting, or any Major Adverse Cardia Event (MACE) defined as cardiac death, CTS-treated vessel myocardial infarction, CTS-treated lesion revascularization, rehospitalization for unstable or progressive angina adjudicated to the CTS-treated lesion 90 days post-procedure
Secondary Safety: Rate of Cryotherapy related events Any cryotherapy procedure related complication defined as coronary artery dissection (angiographic dissection = NHLBI type B), acute vessel closure, life threatening arrythmia, need for bailout stenting, or any MACE defined as cardiac death, CTS-treated vessel myocardial infarction, CTS-treated lesion revascularization, rehospitalization for unstable or progressive angina adjudicated to the CTS-treated lesion 1 year post-procedure
Secondary Device success Number of lesions successfully treated without device deficiency end of CTS treatment
Secondary CTS procedure success Number of lesions successfully treated to obtain Thrombolysis in Myocardial Infarction (TIMI) 3 flow end of CTS treatment
Secondary Imaging: CCTA assessed Minimum lumen area (MLA) Change in MLA (mm²) compared to baseline 90 days post-procedure
Secondary Imaging: CCTA assessed Minimum lumen area (MLA) Change in MLA (mm²) compared to baseline 9 months post-procedure
Secondary Imaging: CCTA assessed area stenosis Change in area stenosis % compared to baseline 3 months post-procedure
Secondary Imaging: CCTA assessed area stenosis Change in area stenosis % compared to baseline 9 months post-procedure
Secondary Imaging: CCTA assessed lesion plaque burden Change in lesion plaque burden % from baseline 3 months post-procedure
Secondary Imaging: CCTA assessed lesion plaque burden Change in lesion plaque burden from baseline 9 months post-procedure
Secondary Imaging: CCTA assessed Total plaque volume Change in total plaque volume (mm³) from baseline 3 months post-procedure
Secondary Imaging: CCTA assessed Total plaque volume Change in total plaque volume(mm³) from baseline 9 months post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A